Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

01-12-2021 | Respiratory Microbiota | Review

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Authors: Yang Yang, Bing Zhao, Xuejiao Gao, Jinbing Sun, Juan Ye, Jun Li, Peng Cao

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Abstract

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and potentially permanent side effect of cancer treatment. For the management of OIPN, accurate diagnosis and understanding of significant risk factors including genetic vulnerability are essential to improve knowledge regarding the prevalence and incidence of OIPN as well as enhance strategies for the prevention and treatment of OIPN. The molecular mechanisms underlying OIPN are complex, with multi-targets and various cells causing neuropathy. Furthermore, mechanisms of OIPN can reinforce each other, and combination therapies may be required for effective management. However, despite intense investigation in preclinical and clinical studies, no preventive therapies have shown significant clinical efficacy, and the established treatment for painful OIPN is limited. Duloxetine is the only agent currently recommended by the American Society of Clinical Oncology. The present article summarizes the most recent advances in the field of studies on OIPN, the overview of the clinical syndrome, molecular basis, therapy development, and outlook of future drug candidates. Importantly, closer links between clinical pain management teams and oncology will advance the effectiveness of OIPN treatment, and the continued close collaboration between preclinical and clinical research will facilitate the development of novel prevention and treatments for OIPN.
Literature
1.
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38:3325–48.PubMedCrossRef
2.
3.
Brozou V, Vadalouca A, Zis P. Pain in platin-induced neuropathies: a systematic review and meta-analysis. Pain Ther. 2018;7:105–19.PubMedCrossRef
4.
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461–70.PubMedCrossRef
5.
Li GZ, Hu YH, Li DY, Zhang Y, Guo HL, Li YM, et al. Vincristine-induced peripheral neuropathy: a mini-review. Neurotoxicology. 2020;81:161–71.PubMedCrossRef
6.
Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings. Crit Rev Oncol Hematol. 2020;145:102831.PubMedCrossRef
7.
Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clin Oncol. 2015;33:3416–22.PubMedPubMedCentralCrossRef
8.
Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. J Crohns Colitis. 2013;7:257–62.PubMedCrossRef
9.
Mason JM, Rees GJ. Oxaliplatin-induced acute thrombocytopenia. J Oncol Pharm Pract. 2011;17:433–5.PubMedCrossRef
10.
Han CH, Kilfoyle DH, Hill AG, Jameson MB, McKeage MJ. Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. Expert Opin Drug Metab Toxicol. 2016;12:1479–90.PubMedCrossRef
11.
Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54:587–91.PubMedCrossRef
12.
Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85:2293–7.PubMedCrossRef
13.
Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004;29:387–92.PubMedCrossRef
14.
Alberti P, Canta A, Chiorazzi A, Fumagalli G, Meregalli C, Monza L, et al. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity. Neuropharmacology. 2020;164:107905.PubMedCrossRef
15.
Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22:1999–2007.PubMedCrossRef
16.
Griffith KA, Zhu S, Johantgen M, Kessler MD, Renn C, Beutler AS, et al. Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer. J Pain Symptom Manag. 2017;54:701–706.e701.CrossRef
17.
Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain. 2016;157:560–8.PubMedCrossRef
18.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.PubMedCrossRef
19.
Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, et al. Chemotherapy-induced neuropathy in cancer survivors. J Pain Symptom Manag. 2017;54:204–18 e202.CrossRef
20.
Staff NP, Cavaletti G, Islam B, Lustberg M, Psimaras D, Tamburin S. Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S26–39.PubMedPubMedCentral
21.
22.
Sharma S, Venkitaraman R, Vas PR, Rayman G. Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction. Brain Behav. 2015;5:e00354.PubMedPubMedCentralCrossRef
23.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.PubMedCrossRef
24.
Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53:1660–4.PubMedCrossRef
25.
Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 2000;54:943–9.PubMedCrossRef
26.
Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012;20:625–32.PubMedCrossRef
27.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.PubMedCrossRef
28.
29.
Ferdousi M, Azmi S, Petropoulos IN, Fadavi H, Ponirakis G, Marshall A, et al. Corneal confocal microscopy detects small fibre neuropathy in patients with upper gastrointestinal cancer and nerve regeneration in chemotherapy induced peripheral neuropathy. PLoS One. 2015;10:e0139394.PubMedPubMedCentralCrossRef
30.
Heuvel S, Doorduin J, Steegers MAH, Bronkhorst EM, Radema SA, Vissers KCP, et al. Simple surface EMG recording as a noninvasive screening method for the detection of acute oxaliplatin-induced neurotoxicity: a feasibility pilot study. Neurosci Lett. 2019;699:184–8.PubMedCrossRef
31.
Dilsizian SE, Siegel EL. Artificial intelligence in medicine and cardiac imaging: harnessing big data and advanced computing to provide personalized medical diagnosis and treatment. Curr Cardiol Rep. 2014;16:441.PubMedCrossRef
32.
33.
Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14–27.PubMedCrossRef
34.
van Hecke O, Kamerman PR, Attal N, Baron R, Bjornsdottir G, Bennett DLH, et al. Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations. Pain. 2015;156:2337–53.PubMedPubMedCentralCrossRef
35.
Cavaletti G, Alberti P, Argyriou AA, Lustberg M, Staff NP, Tamburin S, et al. Chemotherapy-induced peripheral neurotoxicity: a multifaceted, still unsolved issue. J Peripher Nerv Syst. 2019;24(Suppl 2):S6–S12.PubMed
36.
Meregalli C, Fumagalli G, Alberti P, Canta A, Chiorazzi A, Monza L, et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy-induced peripheral neurotoxicity. Arch Toxicol. 2020;94:2517–22.PubMedCrossRef
37.
Tsubota M, Fukuda R, Hayashi Y, Miyazaki T, Ueda S, Yamashita R, et al. Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants. J Neuroinflammation. 2019;16:199.PubMedPubMedCentralCrossRef
38.
Roldan CJ, Johnson C, Lee SO, Peng A, Dougherty PM, Huh B. Subclinical peripheral neuropathy in patients with head and neck cancer: a quantitative sensory testing (QST) study. Pain Physician. 2018;21:E419–27.PubMedPubMedCentralCrossRef
39.
de Carvalho BM, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, et al. A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res. 2014;74:5955–62.CrossRef
40.
Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepere C, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144:245–52.PubMedCrossRef
41.
Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol. 2017;28:2733–40.PubMedCrossRef
42.
Sanchez-Barroso L, Apellaniz-Ruiz M, Gutierrez-Gutierrez G, Santos M, Roldan-Romero JM, Curras M, et al. Concomitant medications and risk of chemotherapy-induced peripheral neuropathy. Oncologist. 2019;24:e784–92.PubMedCrossRef
43.
Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018;89:636–41.PubMedCrossRef
44.
Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, et al. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest. 2018;128:816–25.PubMedPubMedCentralCrossRef
45.
Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol. 2013;71:843–51.PubMedCrossRef
46.
Johnson C, Pankratz VS, Velazquez AI, Aakre JA, Loprinzi CL, Staff NP, et al. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci. 2015;349:124–8.PubMedPubMedCentralCrossRef
47.
Qian CY, Zheng Y, Wang Y, Chen J, Liu JY, Zhou HH, et al. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chin J Cancer. 2016;35:85.PubMedPubMedCentralCrossRef
48.
Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013;110:11199–204.PubMedPubMedCentralCrossRef
49.
Mori Y, Katsumata K, Tsuchida A, Aoki T. Single nucleotide polymorphism analysis in the GSTP1 and ABCC2 genes about neuropathy by the Oxaliplatin. Gan To Kagaku Ryoho. 2008;35:2377–81.PubMed
50.
Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne LB, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007;13:6359–68.PubMedCrossRef
51.
Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. 2013;119:3570–7.PubMedCrossRef
52.
Sereno M, Gutierrez-Gutierrez G, Rubio JM, Apellaniz-Ruiz M, Sanchez-Barroso L, Casado E, et al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer. 2017;17:63.PubMedPubMedCentralCrossRef
53.
Marmiroli P, Riva B, Pozzi E, Ballarini E, Lim D, Chiorazzi A, et al. Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: phenotypic and genotypic insights. PLoS One. 2017;12:e0186250.PubMedPubMedCentralCrossRef
54.
Cliff J, Jorgensen AL, Lord R, Azam F, Cossar L, Carr DF, et al. The molecular genetics of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;120:127–40.PubMedCrossRef
55.
Sittl R, Lampert A, Huth T, Schuy ET, Link AS, Fleckenstein J, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A. 2012;109:6704–9.PubMedPubMedCentralCrossRef
56.
Egashira N, Hirakawa S, Kawashiri T, Yano T, Ikesue H, Oishi R. Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. J Pharmacol Sci. 2010;112:473–6.PubMedCrossRef
57.
Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015;20:411–32.PubMedPubMedCentralCrossRef
58.
Chen HP, Zhou W, Kang LM, Yan H, Zhang L, Xu BH, et al. Intrathecal miR-96 inhibits Nav1.3 expression and alleviates neuropathic pain in rat following chronic construction injury. Neurochem Res. 2014;39:76–83.PubMedCrossRef
59.
Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology. 2008;29:1100–6.PubMedCrossRef
60.
Kerckhove N, Busserolles J, Stanbury T, Pereira B, Plence V, Bonnetain F, et al. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. BMJ Open. 2019;9:e027770.PubMedPubMedCentralCrossRef
61.
Poupon L, Lamoine S, Pereira V, Barriere DA, Lolignier S, Giraudet F, et al. Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology. 2018;140:43–61.PubMedCrossRef
62.
Anon B, Largeau B, Girault A, Chantome A, Caulet M, Perray C, et al. Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity. Cancer Chemother Pharmacol. 2018;82:149–57.PubMedCrossRef
63.
Siau C, Bennett GJ. Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg. 2006;102:1485–90.PubMedPubMedCentralCrossRef
64.
Furgala A, Fijalkowski L, Nowaczyk A, Salat R, Salat K. Time-shifted co-administration of sub-analgesic doses of ambroxol and pregabalin attenuates oxaliplatin-induced cold allodynia in mice. Biomed Pharmacother. 2018;106:930–40.PubMedCrossRef
65.
Yamamoto K, Tsuboi M, Kambe T, Abe K, Nakatani Y, Kawakami K, et al. Oxaliplatin administration increases expression of the voltage-dependent calcium channel alpha2delta-1 subunit in the rat spinal cord. J Pharmacol Sci. 2016;130:117–22.PubMedCrossRef
66.
Schmitt LI, Leo M, Kleinschnitz C, Hagenacker T. Oxaliplatin modulates the characteristics of voltage-gated calcium channels and action potentials in small dorsal root ganglion neurons of rats. Mol Neurobiol. 2018;55:8842–55.PubMedCrossRef
67.
Yang Y, Luo L, Cai X, Fang Y, Wang J, Chen G, et al. Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function. Free Radic Biol Med. 2018;120:13–24.PubMedCrossRef
68.
69.
Gauchan P, Andoh T, Kato A, Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett. 2009;458:93–5.PubMedCrossRef
70.
Miyake T, Nakamura S, Meng Z, Hamano S, Inoue K, Numata T, et al. Distinct mechanism of cysteine oxidation-dependent activation and cold sensitization of human transient receptor potential Ankyrin 1 channel by high and low Oxaliplatin. Front Physiol. 2017;8:878.PubMedPubMedCentralCrossRef
71.
Nakagawa T, Kaneko S. Roles of transient receptor potential Ankyrin 1 in Oxaliplatin-induced peripheral neuropathy. Biol Pharm Bull. 2017;40:947–53.PubMedCrossRef
72.
Cavaletti G, Ceresa C, Nicolini G, Marmiroli P. Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity. Anticancer Res. 2014;34:483–6.PubMed
73.
Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci. 1998;46:342–51.PubMed
74.
75.
Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis. 2011;41:661–8.PubMedCrossRef
76.
Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N, et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain. 2011;152:1621–31.PubMedCrossRef
77.
Chine VB, Au NPB, Kumar G, Ma CHE. Targeting axon integrity to prevent chemotherapy-induced peripheral neuropathy. Mol Neurobiol. 2019;56:3244–59.PubMedCrossRef
78.
Lim SC, Choi JE, Kang HS, Han SI. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer. 2010;126:1582–95.PubMed
79.
Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol. 2011;232:154–61.PubMedPubMedCentralCrossRef
80.
Fang Y, Ye J, Zhao B, Sun J, Gu N, Chen X, et al. Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis. Redox Biol. 2020;36:101677.PubMedPubMedCentralCrossRef
81.
Maruta T, Nemoto T, Hidaka K, Koshida T, Shirasaka T, Yanagita T, et al. Upregulation of ERK phosphorylation in rat dorsal root ganglion neurons contributes to oxaliplatin-induced chronic neuropathic pain. PLoS One. 2019;14:e0225586.PubMedPubMedCentralCrossRef
82.
Brandolini L, Castelli V, Aramini A, Giorgio C, Bianchini G, Russo R, et al. DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain. Sci Rep. 2019;9:11729.PubMedPubMedCentralCrossRef
83.
Shen S, Lim G, You Z, Ding W, Huang P, Ran C, et al. Gut microbiota is critical for the induction of chemotherapy-induced pain. Nat Neurosci. 2017;20:1213–6.PubMedPubMedCentralCrossRef
84.
Makker PG, Duffy SS, Lees JG, Perera CJ, Tonkin RS, Butovsky O, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS One. 2017;12:e0170814.PubMedPubMedCentralCrossRef
85.
Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003;306:624–30.PubMedCrossRef
86.
Zhang T, Zhang J, Shi J, Feng Y, Sun ZS, Li H. Antinociceptive synergistic effect of spinal mGluR2/3 antagonist and glial cells inhibitor on peripheral inflammation-induced mechanical hypersensitivity. Brain Res Bull. 2009;79:219–23.PubMedCrossRef
87.
Di Cesare Mannelli L, Pacini A, Matera C, Zanardelli M, Mello T, De Amici M, et al. Involvement of alpha7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacology. 2014;79:37–48.PubMedCrossRef
88.
Di Cesare Mannelli L, Pacini A, Micheli L, Tani A, Zanardelli M, Ghelardini C. Glial role in oxaliplatin-induced neuropathic pain. Exp Neurol. 2014;261:22–33.PubMedCrossRef
89.
Di Cesare Mannelli L, Pacini A, Bonaccini L, Zanardelli M, Mello T, Ghelardini C. Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. J Pain. 2013;14:1585–600.PubMedCrossRef
90.
Imai S, Koyanagi M, Azimi Z, Nakazato Y, Matsumoto M, Ogihara T, et al. Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Sci Rep. 2017;7:5947.PubMedPubMedCentralCrossRef
91.
Salat K, Kolaczkowski M, Furgala A, Rojek A, Sniecikowska J, Varney MA, et al. Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain. Neuropharmacology. 2017;125:181–8.PubMedCrossRef
92.
Hache G, Guiard BP, Nguyen TH, Quesseveur G, Gardier AM, Peters D, et al. Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain. Eur J Pain. 2015;19:322–33.PubMedCrossRef
93.
Potenzieri A, Riva B, Genazzani AA. Unexpected Ca(2+)-mobilization of oxaliplatin via H1 histamine receptors. Cell Calcium. 2020;86:102128.PubMedCrossRef
94.
Yamamoto S, Ushio S, Egashira N, Kawashiri T, Mitsuyasu S, Higuchi H, et al. Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. Sci Rep. 2017;7:9661.PubMedPubMedCentralCrossRef
95.
Soni N, Reddy BV, Kumar P. GLT-1 transporter: an effective pharmacological target for various neurological disorders. Pharmacol Biochem Behav. 2014;127:70–81.PubMedCrossRef
96.
Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27:992–1002.PubMedCrossRef
97.
Norcini M, Vivoli E, Galeotti N, Bianchi E, Bartolini A, Ghelardini C. Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. Pain. 2009;146:141–7.PubMedCrossRef
98.
Jiang SP, Zhang ZD, Kang LM, Wang QH, Zhang L, Chen HP. Celecoxib reverts oxaliplatin-induced neuropathic pain through inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion. Exp Neurol. 2016;275(Pt 1):11–6.PubMedCrossRef
99.
Ito N, Sakai A, Miyake N, Maruyama M, Iwasaki H, Miyake K, et al. Suzuki H: miR-15b mediates oxaliplatin-induced chronic neuropathic pain through BACE1 down-regulation. Br J Pharmacol. 2017;174:386–95.PubMedPubMedCentralCrossRef
100.
Schafers M, Sorkin L. Effect of cytokines on neuronal excitability. Neurosci Lett. 2008;437:188–93.PubMedCrossRef
101.
Trevisan G, Materazzi S, Fusi C, Altomare A, Aldini G, Lodovici M, et al. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res. 2013;73:3120–31.PubMedCrossRef
102.
Meseguer V, Alpizar YA, Luis E, Tajada S, Denlinger B, Fajardo O, et al. TRPA1 channels mediate acute neurogenic inflammation and pain produced by bacterial endotoxins. Nat Commun. 2014;5:3125.PubMedCrossRef
103.
Zhong S, Zhou Z, Liang Y, Cheng X, Li Y, Teng W, et al. Targeting strategies for chemotherapy-induced peripheral neuropathy: does gut microbiota play a role? Crit Rev Microbiol. 2019;45:369–93.PubMedCrossRef
104.
Gui QF, Lu HF, Zhang CX, Xu ZR, Yang YH. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res. 2015;14:5642–51.PubMedCrossRef
105.
Deuis JR, Zimmermann K, Romanovsky AA, Possani LD, Cabot PJ, Lewis RJ, et al. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. Pain. 2013;154:1749–57.PubMedPubMedCentralCrossRef
106.
Lainez S, Tsantoulas C, Biel M, McNaughton PA. HCN3 ion channels: roles in sensory neuronal excitability and pain. J Physiol. 2019;597:4661–75.PubMedCrossRef
107.
108.
Sittl R, Carr RW, Fleckenstein J, Grafe P. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. Neurotoxicology. 2010;31:694–700.PubMedCrossRef
109.
Materazzi S, Fusi C, Benemei S, Pedretti P, Patacchini R, Nilius B, et al. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pflugers Arch. 2012;463:561–9.PubMedCrossRef
110.
Wahl P, Foged C, Tullin S, Thomsen C. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol. 2001;59:9–15.PubMedCrossRef
111.
Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.PubMedCrossRef
112.
Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF, et al. Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother Pharmacol. 2009;64:847–56.PubMedCrossRef
113.
Jimenez-Andrade JM, Herrera MB, Ghilardi JR, Vardanyan M, Melemedjian OK, Mantyh PW. Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. Mol Pain. 2008;4:10.PubMedPubMedCentralCrossRef
114.
Streckmann F, Balke M, Lehmann HC, Rustler V, Koliamitra C, Elter T, et al. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP. BMC Cancer. 2018;18:62.PubMedPubMedCentralCrossRef
115.
Miao F, Wang R, Cui G, Li X, Wang T, Li X. Engagement of MicroRNA-155 in exaggerated oxidative stress signal and TRPA1 in the dorsal horn of the spinal cord and neuropathic pain during chemotherapeutic Oxaliplatin. Neurotox Res. 2019;36:712–23.PubMedCrossRef
116.
Chukyo A, Chiba T, Kambe T, Yamamoto K, Kawakami K, Taguchi K, et al. Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity. Neuropeptides. 2018;67:95–101.PubMedCrossRef
117.
Miyake T, Nakamura S, Zhao M, So K, Inoue K, Numata T, et al. Cold sensitivity of TRPA1 is unveiled by the prolyl hydroxylation blockade-induced sensitization to ROS. Nat Commun. 2016;7:12840.PubMedPubMedCentralCrossRef
118.
Cerles O, Goncalves TC, Chouzenoux S, Benoit E, Schmitt A, Bennett Saidu NE, et al. Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth. Acta Neuropathol Commun. 2019;7:9.PubMedPubMedCentralCrossRef
119.
Bobylev I, Joshi AR, Barham M, Neiss WF, Lehmann HC. Depletion of Mitofusin-2 causes mitochondrial damage in cisplatin-induced neuropathy. Mol Neurobiol. 2018;55:1227–35.PubMedCrossRef
120.
Zheng H, Xiao WH, Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol. 2012;238:225–34.PubMedCrossRef
121.
Illias AM, Gist AC, Zhang H, Kosturakis AK, Dougherty PM. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity. Pain. 2018;159:1308–16.PubMedPubMedCentralCrossRef
122.
Gu H, Wang C, Li J, Yang Y, Sun W, Jiang C, et al. High mobility group box-1-toll-like receptor 4-phosphatidylinositol 3-kinase/protein kinase B-mediated generation of matrix metalloproteinase-9 in the dorsal root ganglion promotes chemotherapy-induced peripheral neuropathy. Int J Cancer. 2020;146:2810–21.PubMedCrossRef
123.
Stojanovska V, McQuade RM, Fraser S, Prakash M, Gondalia S, Stavely R, et al. Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. PLoS One. 2018;13:e0198359.PubMedPubMedCentralCrossRef
124.
Janes K, Wahlman C, Little JW, Doyle T, Tosh DK, Jacobson KA, et al. Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. Brain Behav Immun. 2015;44:91–9.PubMedCrossRef
125.
Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG. Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. Pain. 2011;152:170–81.PubMedCrossRef
126.
Xu D, Zhao H, Gao H, Zhao H, Liu D, Li J. Participation of pro-inflammatory cytokines in neuropathic pain evoked by chemotherapeutic oxaliplatin via central GABAergic pathway. Mol Pain. 2018;14:1744806918783535.PubMedPubMedCentral
127.
Salat K, Furgala A, Salat R. Interventional and preventive effects of aripiprazole and ceftriaxone used alone or in combination on oxaliplatin-induced tactile and cold allodynia in mice. Biomed Pharmacother. 2019;111:882–90.PubMedCrossRef
128.
Niedzielska-Andres E, Mizera J, Sadakierska-Chudy A, Pomierny-Chamiolo L, Filip M. Changes in the glutamate biomarker expression in rats vulnerable or resistant to the rewarding effects of cocaine and their reversal by ceftriaxone. Behav Brain Res. 2019;370:111945.PubMedCrossRef
129.
Hajhashemi V, Hosseinzadeh H, Amin B. Antiallodynia and antihyperalgesia effects of ceftriaxone in treatment of chronic neuropathic pain in rats. Acta Neuropsychiatr. 2013;25:27–32.PubMedCrossRef
130.
Fijalkowski L, Salat K, Podkowa A, Zareba P, Nowaczyk A. Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors-molecular docking and pharmacodynamic studies. Eur J Pharm Sci. 2017;96:362–72.PubMedCrossRef
131.
Ren X, Boriero D, Chaiswing L, Bondada S, St Clair DK, Butterfield DA. Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”), a condition that significantly impairs the quality of life of many cancer survivors. Biochim Biophys Acta Mol basis Dis. 1865;2019:1088–97.
132.
Cerulla Torrente N, Navarro Pastor JB, de la Osa Chaparro N. Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. J Cancer Surviv. 2020;14:464–82.PubMedCrossRef
133.
Quintao NLM, Santin JR, Stoeberl LC, Correa TP, Melato J, Costa R. Pharmacological treatment of chemotherapy-induced neuropathic pain: PPARgamma agonists as a promising tool. Front Neurosci. 2019;13:907.PubMedPubMedCentralCrossRef
134.
Rutkove SB. Effects of temperature on neuromuscular electrophysiology. Muscle Nerve. 2001;24:867–82.PubMedCrossRef
135.
Scuteri A, Galimberti A, Ravasi M, Pasini S, Donzelli E, Cavaletti G, et al. NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neurosci Lett. 2010;486:141–5.PubMedCrossRef
136.
Chiu IM, Heesters BA, Ghasemlou N, Von Hehn CA, Zhao F, Tran J, et al. Bacteria activate sensory neurons that modulate pain and inflammation. Nature. 2013;501:52–7.PubMedPubMedCentralCrossRef
137.
Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2019;25:6295–301.PubMedPubMedCentralCrossRef
138.
Poupon L, Kerckhove N, Vein J, Lamoine S, Authier N, Busserolles J, et al. Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives. Expert Opin Drug Saf. 2015;14:1269–82.PubMedCrossRef
139.
Beijers AJM, Bonhof CS, Mols F, Ophorst J, de Vos-Geelen J, Jacobs EMG, et al. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2020;31:131–6.PubMedCrossRef
140.
Eldridge S, Guo L, Hamre J 3rd. A comparative review of chemotherapy-induced peripheral neuropathy in in vivo and in vitro models. Toxicol Pathol. 2020;48:190–201.PubMedCrossRef
141.
Farshchian N, Alavi A, Heydarheydari S, Moradian N. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol. 2018;82:787–93.PubMedCrossRef
142.
Barajas-Martinez HM, Hu D, Cordeiro JM, Wu Y, Kovacs RJ, Meltser H, et al. Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res. 2008;103:396–404.PubMedPubMedCentralCrossRef
143.
van den Heuvel SAS, van der Wal SEI, Smedes LA, Radema SA, van Alfen N, Vissers KCP, et al. Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy. Pain Res Manag. 2017;2017:8053474.PubMedPubMedCentralCrossRef
144.
Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm. 2014;71:19–25.PubMedCrossRef
145.
146.
Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer. 2011;47:369–74.PubMedCrossRef
147.
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29:421–7.PubMedCrossRef
148.
Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32:997–1005.PubMedCrossRef
149.
Han CH, Khwaounjoo P, Kilfoyle DH, Hill A, McKeage MJ. Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. BMC Cancer. 2013;13:495.PubMedPubMedCentralCrossRef
150.
Meng J, Zhang Q, Yang C, Xiao L, Xue Z, Zhu J. Duloxetine, a balanced serotonin-norepinephrine reuptake inhibitor, improves painful chemotherapy-induced peripheral neuropathy by inhibiting activation of p38 MAPK and NF-kappaB. Front Pharmacol. 2019;10:365.PubMedPubMedCentralCrossRef
151.
Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, et al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer. 2016;24:1071–8.PubMedCrossRef
152.
Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23:200–5.PubMedCrossRef
153.
Koukourakis MI, Simopoulos C, Minopoulos G, Patlakas G, Polychronidis A, Limberis V, et al. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin Cancer Res. 2003;9:3288–93.PubMed
154.
Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol. 2001;12:421–2.PubMedCrossRef
155.
Karlsson JOG, Andersson RG, Jynge P. Mangafodipir a selective cytoprotectant - with special reference to Oxaliplatin and its association to chemotherapy-induced peripheral neuropathy (CIPN). Transl Oncol. 2017;10:641–9.PubMedPubMedCentralCrossRef
156.
Coriat R, Alexandre J, Nicco C, Quinquis L, Benoit E, Chereau C, et al. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest. 2014;124:262–72.PubMedCrossRef
157.
Huang CY, Chen YL, Li AH, Lu JC, Wang HL. Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neurons. J Neuroinflammation. 2014;11:7.PubMedPubMedCentralCrossRef
158.
Robinson CR, Zhang H, Dougherty PM. Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat. Neuroscience. 2014;274:308–17.PubMedCrossRef
159.
Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, et al. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer. 2017;25:3407–16.PubMedCrossRef
160.
Soliman AM, Teoh SL, Ghafar NA, Das S. Molecular concept of diabetic wound healing: effective role of herbal remedies. Mini Rev Med Chem. 2019;19:381–94.PubMedCrossRef
161.
Miguel CA, Raggio MC, Villar MJ, Gonzalez SL, Coronel MF. Anti-allodynic and anti-inflammatory effects of 17alpha-hydroxyprogesterone caproate in oxaliplatin-induced peripheral neuropathy. J Peripher Nerv Syst. 2019;24:100–10.PubMedCrossRef
162.
Wang W, Xiang P, Chew WS, Torta F, Bandla A, Lopez V, et al. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. J Biol Chem. 2020;295:1143–52.PubMedCrossRef
163.
Bruna J, Velasco R. Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy. Neural Regen Res. 2018;13:775–8.PubMedPubMedCentralCrossRef
164.
Toyama S, Shimoyama N, Ishida Y, Koyasu T, Szeto HH, Shimoyama M. Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies. Anesthesiology. 2014;120:459–73.PubMedCrossRef
165.
Resta F, Micheli L, Laurino A, Spinelli V, Mello T, Sartiani L, et al. Selective HCN1 block as a strategy to control oxaliplatin-induced neuropathy. Neuropharmacology. 2018;131:403–13.PubMedCrossRef
166.
Salat K, Furgala A, Salat R. Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain. Inflammopharmacology. 2018;26:361–74.PubMedCrossRef
167.
Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Br J Anaesth. 2017;119:737–49.PubMedCrossRef
168.
Chlon-Rzepa G, Slusarczyk M, Jankowska A, Gawalska A, Bucki A, Kolaczkowski M, et al. Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: a new approach for the treatment of pain. Eur J Med Chem. 2018;158:517–33.PubMedCrossRef
169.
Choucry AM, Al-Shorbagy MY, Attia AS, El-Abhar HS. Pharmacological manipulation of Trk, p75NTR, and NGF balance restores memory deficit in global ischemia/reperfusion model in rats. J Mol Neurosci. 2019;68:78–90.PubMedCrossRef
170.
Gong G, Yin L, Yuan L, Sui D, Sun Y, Fu H, et al. Ganglioside GM1 protects against high altitude cerebral edema in rats by suppressing the oxidative stress and inflammatory response via the PI3K/AKT-Nrf2 pathway. Mol Immunol. 2018;95:91–8.PubMedCrossRef
171.
Defaye M, Gervason S, Altier C, Berthon JY, Ardid D, Filaire E, et al. Microbiota: a novel regulator of pain. J Neural Transm (Vienna). 2020;127:445–65.CrossRef
172.
Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol. 2015;54:463–9.PubMedCrossRef
173.
Derksen TM, Bours MJ, Mols F, Weijenberg MP. Lifestyle-related factors in the self-management of chemotherapy-induced peripheral neuropathy in colorectal cancer: a systematic review. Evid Based Complement Alternat Med. 2017;2017:7916031.PubMedPubMedCentralCrossRef
174.
Gewandter JS, Gibbons CH, Campagnolo M, Lee J, Chaudari J, Ward N, et al. Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review. Neurology. 2019;93:346–60.PubMedCrossRef
175.
Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011;3:266–78.PubMedPubMedCentralCrossRef
176.
Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain. 2007;128:225–34.PubMedCrossRef
177.
Shamban A. Safety and efficacy of facial rejuvenation with small gel particle hyaluronic acid with lidocaine and AbobotulinumtoxinA in post-chemotherapy patients: a phase IV investigator-initiated study. J Clin Aesthet Dermatol. 2014;7:31–6.PubMedPubMedCentral
178.
Gauchan P, Andoh T, Ikeda K, Fujita M, Sasaki A, Kato A, et al. Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. Biol Pharm Bull. 2009;32:732–4.PubMedCrossRef
179.
Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010;30:2927–33.PubMed
180.
de Andrade DC, Jacobsen Teixeira M, Galhardoni R, Ferreira KSL, Braz Mileno P, Scisci N, et al. Pregabalin for the prevention of Oxaliplatin-induced painful neuropathy: a randomized, double-blind trial. Oncologist. 2017;22:1154–e1105.PubMedPubMedCentralCrossRef
181.
Salat K, Furgala A, Malikowska-Racia N. Searching for analgesic drug candidates alleviating oxaliplatin-induced cold hypersensitivity in mice. Chem Biol Drug Des. 2019;93:1061–72.PubMed
182.
Higgins GA, Fletcher PJ, Shanahan WR. Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol Ther. 2020;205:107417.PubMedCrossRef
183.
Smith EM, Pang H, Ye C, Cirrincione C, Fleishman S, Paskett ED, et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. Eur J Cancer Care (Engl). 2017;(2):26. https://​doi.​org/​10.​1111/​ecc.​12421.
184.
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67.PubMedPubMedCentralCrossRef
185.
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–67.PubMedCrossRef
186.
Guillaumot MA, Cerles O, Bertrand HC, Benoit E, Nicco C, Chouzenoux S, et al. Oxaliplatin-induced neuropathy: the preventive effect of a new super-oxide dismutase modulator. Oncotarget. 2019;10:6418–31.PubMedPubMedCentralCrossRef
187.
Qin Y, Iwase A, Murase T, Bayasula, Ishida C, Kato N, et al. Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice. Reprod Biol Endocrinol. 2018;16:106.PubMedPubMedCentralCrossRef
188.
Glimelius B, Manojlovic N, Pfeiffer P, Mosidze B, Kurteva G, Karlberg M, et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx((R))): a placebo-controlled randomised phase II study (PLIANT). Acta Oncol. 2018;57:393–402.PubMedCrossRef
189.
Boyette-Davis J, Dougherty PM. Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol. 2011;229:353–7.PubMedPubMedCentralCrossRef
190.
Kelley MR, Wikel JH, Guo C, Pollok KE, Bailey BJ, Wireman R, et al. Identification and characterization of new chemical entities targeting Apurinic/Apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy. J Pharmacol Exp Ther. 2016;359:300–9.PubMedPubMedCentralCrossRef
191.
Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, et al. The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. J Biol Chem. 2014;289:21082–97.PubMedPubMedCentralCrossRef
192.
Zhang L, Wang H. FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide. Pharmacol Rep. 2017;69:1186–93.PubMedCrossRef
193.
Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, et al. The National Cancer Institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst. 2019;111:531–7.PubMedPubMedCentralCrossRef
194.
Bruna J, Videla S, Argyriou AA, Velasco R, Villoria J, Santos C, et al. Efficacy of a novel Sigma-1 receptor antagonist for Oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial. Neurotherapeutics. 2018;15:178–89.PubMedCrossRef
195.
Potenzieri A, Riva B, Rigolio R, Chiorazzi A, Pozzi E, Ballarini E, et al. Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors. Pain. 2020;161:405–15.PubMedCrossRef
196.
Nativi C, Gualdani R, Dragoni E, Di Cesare Mannelli L, Sostegni S, Norcini M, et al. A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain. Sci Rep. 2013;3:2005.PubMedPubMedCentralCrossRef
197.
Yehia R, Saleh S, El Abhar H, Saad AS, Schaalan M. L-carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a perspective on targeting Nrf-2 and NF-kappaB pathways. Toxicol Appl Pharmacol. 2019;365:41–50.PubMedCrossRef
198.
Wang DS, Wang ZQ, Chen G, Peng JW, Wang W, Deng YH, et al. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. Cancer Med. 2020;9:151–9.PubMedCrossRef
199.
200.
Maindrault-Goebel F, Tournigand C, Andre T, Carola E, Mabro M, Artru P, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol. 2004;15:1210–4.PubMedCrossRef
201.
Yamamoto S, Yamashita T, Ito M, Caaveiro JMM, Egashira N, Tozaki-Saitoh H, et al. New pharmacological effect of fulvestrant to prevent oxaliplatin-induced neurodegeneration and mechanical allodynia in rats. Int J Cancer. 2019;145:2107–13.PubMedCrossRef
202.
Cerles O, Benoit E, Chereau C, Chouzenoux S, Morin F, Guillaumot MA, et al. Niclosamide inhibits Oxaliplatin neurotoxicity while improving colorectal cancer therapeutic response. Mol Cancer Ther. 2017;16:300–11.PubMedCrossRef
203.
Al-Massri KF, Ahmed LA, El-Abhar HS. Mesenchymal stem cells in chemotherapy-induced peripheral neuropathy: a new challenging approach that requires further investigations. J Tissue Eng Regen Med. 2020;14:108–22.PubMedCrossRef
204.
Shiragami R, Murata S, Kosugi C, Tezuka T, Yamazaki M, Hirano A, et al. Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells. Int J Oncol. 2013;43:431–8.PubMedCrossRef
205.
Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32:51–60.PubMedCrossRef
206.
Toume K, Hou Z, Yu H, Kato M, Maesaka M, Bai Y, et al. Search of anti-allodynic compounds from Plantaginis Semen, a crude drug ingredient of Kampo formula “Goshajinkigan”. J Nat Med. 2019;73:761–8.PubMedPubMedCentralCrossRef
207.
Cheng X, Huo J, Wang D, Cai X, Sun X, Lu W, et al. Herbal medicine AC591 prevents Oxaliplatin-induced peripheral neuropathy in animal model and cancer patients. Front Pharmacol. 2017;8:344.PubMedPubMedCentralCrossRef
208.
Zhang QY, Wang FX, Jia KK, Kong LD. Natural product interventions for chemotherapy and radiotherapy-induced side effects. Front Pharmacol. 2018;9:1253.PubMedPubMedCentralCrossRef
209.
Wu BY, Liu CT, Su YL, Chen SY, Chen YH, Tsai MY. A review of complementary therapies with medicinal plants for chemotherapy-induced peripheral neuropathy. Complement Ther Med. 2019;42:226–32.PubMedCrossRef
210.
Andrews NA, Latremoliere A, Basbaum AI, Mogil JS, Porreca F, Rice ASC, et al. Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerations. Pain. 2016;157:901–9.PubMedCrossRef
211.
Mogil JS. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci. 2012;13:859–66.PubMedCrossRef
Metadata
Title
Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development
Authors
Yang Yang
Bing Zhao
Xuejiao Gao
Jinbing Sun
Juan Ye
Jun Li
Peng Cao
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02141-z

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue

Correction

Correction to: Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest

Correction

Correction to: YPEL3 suppresses epithelial–mesenchymal transition and metastasis of nasopharyngeal carcinoma cells through the Wnt/β-catenin signaling pathway

Review

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Research

Let-7a regulates EV secretion and mitochondrial oxidative phosphorylation by targeting SNAP23 in colorectal cancer

Research

An SETD1A/Wnt/β-catenin feedback loop promotes NSCLC development

Research

ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits